Company Analysis
Sign in

Janux Therapeutics, Inc. (JANX)

Nasdaq: JANX · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2020
Full chart Alerts Compare
Grade5.0
◀ Past 5.1● Present 6.1▶ Future 4.1
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

4 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Janux Therapeutics, Inc.’s names, not what it holds today.

Patents granted
4
4 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 1 in 2024 and 1 in 2023
Applications published
29
5 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'18'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Biotechnology2
Pharmaceuticals2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Janux Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
29 published
JANUX THERAPEUTICS, INC. its own name
US, as the owner printed on each patent
4 granted
0 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Oct 7, 202512,433,953Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigensPharmaceuticalsJANUX THERAPEUTICS, INC.
Dec 10, 202412,161,724Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigensPharmaceuticalsJANUX THERAPEUTICS, INC.
Jan 17, 202311,555,078Compositions and methods related to tumor activated antibodies targeting PSMA and effector cell antigensBiotechnologyJANUX THERAPEUTICS, INC.
Nov 29, 202211,512,113Cleavable linker compositions and methodsBiotechnologyJANUX THERAPEUTICS, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Sep 25, 20252025/0297017COMPOSITIONS AND USES OF TUMOR ACTIVATED ANTIBODIES TARGETING EGFR AND EFFECTOR CELL ANTIGENSPharmaceuticalsJanux Therapeutics, Inc.
Aug 7, 20252025/0250339ANTIBODIES TARGETING EGFR AND CD3 AND USES THEREOFBiotechnologyJanux Therapeutics, Inc.
Jun 5, 20252025/0177552COMPOSITIONS AND METHODS RELATED TO TUMOR ACTIVATED ANTIBODIES TARGETING EGFR AND EFFECTOR CELL ANTIGENSPharmaceuticalsJanux Therapeutics, Inc. · patent 12,433,953 granted from it
May 15, 20252025/0154278OPTIMIZED ANTIBODIES TARGETING TROP2 AND USES THEREOFBiotechnologyJanux Therapeutics, Inc.
Jan 16, 20252025/0019403CLEAVABLE LINKER COMPOSITIONS AND METHODSBiotechnologyJanux Therapeutics, Inc.
Nov 14, 20242024/0376226COMPOSITIONS AND METHODS RELATING TO TUMOR ACTIVATED T CELL ENGAGERSBiotechnologyJanux Therapeutics, Inc.
Aug 1, 20242024/0254241ANTIBODIES TARGETING EGFR AND CD3 AND USES THEREOFBiotechnologyJanux Therapeutics, Inc.
Aug 1, 20242024/0252669COMPOSITIONS AND METHODS RELATED TO TUMOR ACTIVATED ANTIBODIES TARGETING EGFR AND EFFECTOR CELL ANTIGENSPharmaceuticalsJanux Therapeutics, Inc. · patent 12,161,724 granted from it
Mar 21, 20242024/0092931ANTIBODIES TARGETING TROP2 AND CD3 AND USES THEREOFBiotechnologyJanux Therapeutics, Inc.
Feb 22, 20242024/0059790COMPOSITIONS AND METHODS RELATED TO TUMOR ACTIVATED ANTIBODIES TARGETING PSMA AND EFFECTOR CELL ANTIGENSBiotechnologyJanux Therapeutics, Inc.
What it applied for, 2024 to 2025: Biotechnology 11 · Pharmaceuticals 3.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton JANX · research, not advice